SRRK Scholar Rock Holding Corporation

10.89
-0.24  -2%
Previous Close 11.13
Open 11.03
Price To Book 2.51
Market Cap 323,218,794
Shares 29,680,330
Volume 30,667
Short Ratio
Av. Daily Volume 96,875

NewsSee all news

  1. Scholar Rock Announces Appointment of George Nomikos, M.D., Ph.D., as Vice President, Head of Medical Research, Muscle Franchise

    CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth

  2. Scholar Rock to Present at Upcoming Healthcare Conferences

    CAMBRIDGE, Mass., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth

  3. Scholar Rock Announces Upcoming Departure of Chief Financial Officer

    CAMBRIDGE, Mass., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ:SRRK), a clinical stage biopharmaceutical company, announced today that its Chief Financial Officer, Rhonda Chicko, will be

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initial PK/PD data due YE 2019. Interim efficacy data 1H 2020 with top-line data 4Q 2020.
SRK-015 - TOPAZ
Spinal muscular atrophy (SMA
Phase 1 trial to be initiated mid-2020 with initial data due by the end of 2021.
SRK-181
Solid Tumors

Latest News

  1. Scholar Rock Announces Appointment of George Nomikos, M.D., Ph.D., as Vice President, Head of Medical Research, Muscle Franchise

    CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth

  2. Scholar Rock to Present at Upcoming Healthcare Conferences

    CAMBRIDGE, Mass., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth

  3. Scholar Rock Announces Upcoming Departure of Chief Financial Officer

    CAMBRIDGE, Mass., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ:SRRK), a clinical stage biopharmaceutical company, announced today that its Chief Financial Officer, Rhonda Chicko, will be